Abstract:Abstract Background: Cholangiocarcinoma (CCA) is the most common malignancy of the biliary tract with a dismal prognosis. Increasing evidence suggests that tumor microenvironment (TME) is closely associated with cancer prognosis. However, the prognostic signature for CCA based on TME has not yet been reported. This study aimed to develop a TME-related prognostic signature for accurately predicting the prognosis of patients with CCA. Methods: Based on the TCGA database, we calculated the stromal and immune scores using the ESTIMATE algorithm to assess TME in stromal and immune cells derived from CCA. TME-related differentially expressed genes were identified, followed by functional enrichment analysis and PPI network analysis. Univariate Cox regression analysis, Lasso Cox regression model and multivariable Cox regression analysis were performed to identify and construct the TME-related prognostic gene signature. Gene Set Enrichment Analyses (GSEA) was performed to further investigate the potential molecular mechanisms. The correlations between the risk scores and tumor infiltration immune cells were analyzed using Tumor Immune Estimation Resource (TIMER) database. Results: A total of 784 TME-related differentially expressed genes (DEGs) were identified, which were mainly enriched in immune-related processes and pathways. Among these TME-related DEGs, A novel two‑gene signature (including GAD1 and KLRB1) was constructed for CCA prognosis prediction. The AUC of the prognostic model for predicting the survival of patients at 1-, 2-, and 3- years was 0.811, 0.772, and 0.844, respectively. Cox regression analysis showed that the two‑gene signature was an independent prognostic factor. Based on the risk scores of the prognostic model, CCA patients were divided into high- and low-risk groups, and patients with high-risk score had shorter survival time than those with low-risk score. Furthermore, we found that the risk scores were negatively correlated with TME-scores and the number of several tumor infiltration immune cells, including B cells and CD4+ T cells. Conclusion: Our study established a novel TME-related gene signature to predict the prognosis of patients with CCA. This might provide a new understanding of the potential relationship between TME and CCA prognosis, and serve as a prognosis stratification tool for guiding personalized treatment of CCA patients.

Elevated ETV4 expression in cholangiocarcinoma is linked to poor prognosis and may guide targeted therapies

Increased ETV4 expression correlates with estrogen-enhanced proliferation and invasiveness of cholangiocarcinoma cells

ETV4 is a Theranostic Target in Clear Cell Renal Cell Carcinoma That Promotes Metastasis by Activating the Pro-Metastatic Gene FOSL1 in a PI3K-AKT Dependent Manner.

Prognostic value of PEA3 subfamily gene expression in cholangiocarcinoma

ETV4 promotes the progression of cholangiocarcinoma by regulating glycolysis via the TGF-β signaling

Overexpressions of Ck2 Beta and Xiap Are Associated with Poor Prognosis of Patients with Cholangiocarcinoma

Overexpressions of CK2β and XIAP Are Associated with Poor Prognosis of Patients with Cholangiocarcinoma

Screening potential biomarkers of cholangiocarcinoma based on gene chip meta-analysis and small-sample experimental research

Apolipoprotein B is Associated with the Microenvironment of Cholangiocarcinoma

FUT4 promotes the progression of Cholangiocarcinoma by modulating epithelial-mesenchymal transition

Bioinformatics combined with quantitative proteomics analyses and identification of potential biomarkers in cholangiocarcinoma

Transcriptomic Analysis and Identification of Prognostic Biomarkers in Cholangiocarcinoma

Biological effect of ETV4 and the underlying mechanism of its regulatory effect on epithelial‐mesenchymal transition in intrahepatic cholangiocarcinoma cells

Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma

Prediction of Angiopoietin-like Protein 4-related Signaling Pathways in Cholangiocarcinoma Cells

Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment

High Expression of the Tumor Suppressor Protein ITIH5 in Cholangiocarcinomas Correlates with a Favorable Prognosis

Molecular profiling reveals potential targets in cholangiocarcinoma

Ubiquitin-conjugating enzyme E2C (UBE2C) is a prognostic indicator for cholangiocarcinoma

Identification of Prognostic Gene Signature Associated with Tumor Microenvironment of Cholangiocarcinoma

Extrachromosomal circular DNA (eccDNA) characteristics in the bile and plasma of advanced perihilar cholangiocarcinoma patients and the construction of an eccDNA-related gene prognosis model